Sign In
Buy ATRC
$26.20
+0.340 (+1.31%)
At Close: Jun 03, 2026
AtriCure, Inc. (ATRC) Q2 2023 Earnings Call Transcript
07:40pm, Tuesday, 25'th Jul 2023
AtriCure, Inc. (NASDAQ:ATRC ) Q2 2023 Earnings Conference Call July 25, 2023 4:30 PM ET Company Participants Marissa Bych - Vice President-Gilmartin Group Mike Carrel - President & CEO Angie Wirick -
AtriCure (ATRC) Reports Q2 Loss, Tops Revenue Estimates
06:23pm, Tuesday, 25'th Jul 2023
AtriCure (ATRC) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.32 per share a year ago.
AtriCure to Participate at Upcoming Investor Conferences
08:00am, Friday, 21'st Jul 2023
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o
AtriCure to Announce Second Quarter 2023 Financial Results
08:00am, Monday, 03'rd Jul 2023
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o
AtriCure: Operating Leverage Is Required As A Cure
03:43pm, Wednesday, 14'th Jun 2023
AtriCure, Inc. has seen continued momentum in Afib and related markets. The company sees solid revenue growth, which, amidst a retreat in the share price, has resulted in rapidly narrowing sales multi
AtriCure, Inc. (ATRC) Q1 2023 Earnings Call Transcript
09:40pm, Tuesday, 02'nd May 2023
AtriCure, Inc. (NASDAQ:ATRC ) Q1 2023 Earnings Conference Call May 2, 2023 4:30 PM ET Company Participants Marissa Bych – Vice President-Gilmartin Group Mike Carrel – President and Chief Executive
AtriCure (ATRC) Reports Q1 Loss, Tops Revenue Estimates
07:09pm, Tuesday, 02'nd May 2023
AtriCure (ATRC) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.33 per share a year ago.
AtriCure (ATRC) Moves 7.5% Higher: Will This Strength Last?
09:57am, Monday, 27'th Mar 2023
AtriCure (ATRC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
AtriCure, Inc. (ATRC) Q4 2022 Earnings Call Transcript
10:47pm, Tuesday, 21'st Feb 2023
AtriCure, Inc. (NASDAQ:ATRC ) Q4 2022 Earnings Conference Call February 21, 2023 4:30 PM ET Company Participants Marissa Bych - Gilmartin Group, Investor Relations Michael Carrel - President and Chief
AtriCure (ATRC) Reports Q4 Loss, Tops Revenue Estimates
06:49pm, Tuesday, 21'st Feb 2023
AtriCure (ATRC) delivered earnings and revenue surprises of 50% and 0.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
AtriCure: Despite Reasonable Top-Line Growth, No Change To Hold Thesis
02:47am, Thursday, 29'th Dec 2022
A reasonable period of top-line growth across the core portfolio last quarter, coupled with strong guidance for FY22. Despite this, operating losses continue to widen, and NOPAT is thin even when capi
AtriCure to Present at 34th Annual Piper Sandler Healthcare Conference
08:00am, Tuesday, 08'th Nov 2022
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain
AtriCure, Inc. (ATRC) Q3 2022 Earnings Call Transcript
09:31pm, Tuesday, 01'st Nov 2022
AtriCure, Inc. (NASDAQ:ATRC ) Q3 2022 Earnings Conference Call November 1, 2022 4:30 PM ET Company Participants Marissa Bych - Investor Relations Michael Carrel - President and Chief Executive Officer
AtriCure (ATRC) Reports Q3 Loss, Tops Revenue Estimates
07:35pm, Tuesday, 01'st Nov 2022
AtriCure (ATRC) delivered earnings and revenue surprises of -8% and 2.26%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
AtriCure Announces Investor Education Webcast with Hybrid AF Therapy Key Opinion Leaders
08:00am, Tuesday, 06'th Sep 2022
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain
